ZINECARD 250 MG — DIN 02153432
DEXRAZOXANE : 250 MG · PFIZER CANADA ULC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ZINECARD?
ZINECARD 250 MG contains DEXRAZOXANE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02153432, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 03-Feb-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZINECARD used for?
Reducing the incidence and severity of cardiotoxicity associated with doxorubicin in metastatic breast cancer patients who have already experienced a partial response or stable disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Dexrazoxane in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Dexrazoxane, across 5 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JUNO PHARMACEUTICALS CORP. | 2 | 1 | DEXRAZOXANE FOR INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 2 | 1 | ZINECARD | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | DEXRAZOXANE FOR INJECTION | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 250 mg and 500 mg single dose vials. Vial stopper is not made with natural rubber latex. Diluent not provided. |
| Storage | Reconstituted solution: stable 30 min at room temp or 3 hours at 2-8°C. Further diluted solution: stable 1 hour at room temp or 4 hours at 2-8°C. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Dexrazoxane |
|---|---|
| ATC code | V03AF02 |
| AHFS class | 91:04.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02153432 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2153432 |
| Brand name | ZINECARD |
| Generic / active ingredient | DEXRAZOXANE : 250 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | V03AF02 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AF |
| Current status | MARKETED |
| Status date | 03-Feb-2009 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended dosage ratio of Zinecard:doxorubicin is 10:1. Administer by rapid drip intravenous infusion over 15 minutes, starting within 30 minutes prior to doxorubicin. Do not give via IV push.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to dexrazoxane or any ingredient; use as a chemotherapeutic agent; use with non-anthracycline chemotherapy regimens.
Warnings and precautions
Potent drug; use only by experienced physicians. May increase myelosuppression. Risk of second primary malignancies. Monitor cardiac, hepatic, renal function and CBC.
Is Dexrazoxane in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by JUNO PHARMA CANADA INC., last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEXRAZOXANE FOR INJECTION | 250 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | 02544083 |
| DEXRAZOXANE FOR INJECTION | 250 MG | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02557649 |
| DEXRAZOXANE FOR INJECTION | 500 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | 02544091 |
| ZINECARD | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | DORMANT | 02153440 |
2 · Same class — other molecules in ATC V03AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Calcium Folinate | JAMP LEUCOVORIN · LEDERLE LEUCOVORIN · LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML · LEDERLE LEUCOVORIN 350MG/VIAL · +11 more | 21 | 9 | Yes |
| Dexrazoxane | DEXRAZOXANE FOR INJECTION · ZINECARD | 5 | 3 | Yes |
| Mesna | MESNA FOR INJECTION · UROMITEXAN · UROMITEXAN INJ 100MG/ML | 4 | 3 | Yes |
| Rasburicase | FASTURTEC | 2 | 1 | Yes |
| Amifostine | ETHYOL - PWS IV 500MG/VIAL | 1 | 0 | Not in Canada |
| Palifermin | KEPIVANCE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AC | Deferasirox · Deferiprone · Deferoxamine | 57 | 44 |
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AE | Calcium Acetate · Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia · Lanthanum Carbonate · Patiromer Calcium · Polystyrene Sulphonate · +3 more | 40 | 19 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ZINECARD called?
The same molecule, Dexrazoxane, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dexrazoxane | Latin | Iceland |
| Savene | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.